Navigation Links
Common diabetes drug may halt growth of cysts in polycystic kidney disease
Date:11/11/2010

INDIANAPOLIS Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease. PKD does not discriminate by gender or race and affects one in 1,000 adults worldwide.

Researchers from the schools of Science and Medicine at Indiana University-Purdue University Indianapolis and colleagues from the Mayo Clinic report this month in the online peer-reviewed journal PPAR Research that pioglitazone appears to control the growth of PKD cysts.

Using a rat model that has the same genetic mutation as a form of human PKD, the two research groups independently tested a pioglitazone treatment regimen and found that it slowed down both kidney and liver cyst growth by inhibiting a chloride channel in the cells of these organs.

Normally pioglitazone works by making the body more sensitive to its own insulin. However, in studying why this class of drugs causes fluid retention, Bonnie L. Blazer-Yost, Ph.D., professor of biology at the IUPUI School of Science and corresponding author of the new study, serendipitously found that it also inhibits a chloride channel.

"We thought that since this class of drugs inhibits the body's chloride channels, then it would be a good candidate to treat PKD, a disease in which excessive chloride and water are transported into the cysts of the kidneys and the liver causing them to expand," said Blazer-Yost, Ph.D.

A normal kidney is the size of a fist. A polycystic kidney is the size of a football. Currently there is no cure for PKD and therapy options are limited. Organ transplantation is the most common treatment.

"The idea of using a chloride channel inhibitor to treat PKD is not new. What is new is our finding that an insulin sensitizing agent like piogltiazone inhibits chloride channels. The finding that pioglitazone, which has already been approved by the Food and Drug Administration for diabetes, can halt cyst progression and may be an effective and well-tolerated treatment for this chronic disease, is exciting. Confirmation of these results in other animal models of PKD would be a useful next step.

"We know from long-term experience that this drug has a good safety profile. Strategies that minimize adverse events are important when considering treatments for a chronic disease such as PKD," said Blazer-Yost, a physiologist who hopes that human trials of pioglitazone therapy for PKD can be conducted in the near future.


'/>"/>

Contact: Cindy Fox Aisen
caisen@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert  

Related biology news :

1. New book examines health and environmental impacts of common (and not-so-common) chemicals
2. Scientists describe new approach for identifying genetic markers for common diseases
3. Researchers find first genetic evidence for loss of teeth in the common ancestor of baleen whales
4. First genetic link to common migraine exposed
5. Low bone mineral density common in children and teenagers with inflammatory bowel disease
6. Scientists find new twist on drug screening to treat common childhood cancer
7. Common orchid gives scientists hope in face of climate change
8. Pancreatic cancers use fructose, common in the Western diet, to fuel their growth
9. Rare and common genetic variations responsible for high triglyceride levels in blood
10. Heat waves could be commonplace in the US by 2039, Stanford study finds
11. New rust resistance genes added to common beans
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common diabetes drug may halt growth of cysts in polycystic kidney disease
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... ... ... Cynvenio Biosystems, Inc. a leader in personalized medicine technology and ... study in partnership with Allentown, PA-based TME Research . The multi-center registry study ... two years with Cynvenio’s ClearID Breast Cancer blood test. The study goal is to ...
(Date:4/27/2017)... Baltimore, MD (PRWEB) , ... April 27, 2017 ... ... analytics solutions provider for digital pathology, today announced their digital pathology technology has ... Using images provided by five medical centers in The Netherlands as part of ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... flow controllers based on capillary thermal mass flow technology provide exponentially more accurate ... applications. Over 80% of all industrial processes—such as those involving chemical reactions, ...
(Date:4/27/2017)... a distinguished resource for research, development and commercialization of ... Thomas C. Seoh as President and CEO. Mr. Seoh ... becomes Executive Chairman and will continue to serve as ... Thomas Seoh commented, "I am excited and honored ... firm,s remarkable team of life science professionals, all of ...
Breaking Biology Technology: